Get the Stockscreener App
0.3642
3.53%
-0.0038
Immutep Limited Adr stock is traded at $0.3642, with a volume of 215.36K.
It is down -3.53% in the last 24 hours and down -87.04% over the past month.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$0.368
Open:
$0.3696
24h Volume:
215.36K
Relative Volume:
0.18
Market Cap:
$52.70M
Revenue:
-
Net Income/Loss:
$-54.17M
P/E Ratio:
-0.9846
EPS:
-0.3699
Net Cash Flow:
$-39.34M
1W Performance:
-13.96%
1M Performance:
-87.04%
6M Performance:
-79.36%
1Y Performance:
-80.60%
1-Day Range:
$0.3523
$0.3696
1-Week Range:
$0.3518
$0.4099
52-Week Range:
$0.3518
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
0.3576 | 54.23M | 0 | -54.17M | -39.34M | -0.3699 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| Mar-13-26 | Downgrade | Maxim Group | Buy → Hold |
| Mar-13-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-17-26 | Initiated | Citizens | Mkt Outperform |
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - mykxlg.com
IMMP Stock Price, Quote & Chart | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - ChartMill
Immutep (NASDAQ: IMMP) reports positive Phase I progress for LAG-3 agonist IMP761 - Stock Titan
IMMP Investor News: If You Have Suffered Losses in Immutep - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - PR Newswire
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
IMMP Investor Alert: Immutep Ltd. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky - Sahm
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - FinancialContent
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP - Business Wire
On Tuesday, there are stocks with unusual volume. Let's take a look. - ChartMill
IMM:ASX AnnouncementChange in substantial holding17 Mar 2026 - Market Index
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Sahm
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early - Sahm
This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% By Investing.com - Investing.com India
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com
This EverCommerce analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
US Market Preview | PCE in Line; ISPC Soars 86.7%; Oil Spikes Amid Iran’s Leader Talk; AI Wealth Boom Adds 45 Billionaires - Sahm
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Immutep reports positive phase I data for first-in-class autoimmune antibody IMP761 - MSN
Why Immutep Limited (Common Stock) (YP1A) stock is trending on social mediaHealthcare Stock Analysis & Investment Portfolio Recommendations - Bollywood Helpline
Immutep (IMMP) reports positive IMP761 Phase I study update - Stock Titan
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely - Sahm
Will Immutep Limited Depositary Receipt stock see insider buying2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Why Immutep Limited (YP1B) stock is a strong analyst pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - Улправда
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - setenews.com
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - setenews.com
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Finviz
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep Limited (NASDAQ: IMMP)Share Price - intelligentinvestor.com.au
JK Paper slides over 7% after Q1 net profit declines 55% YoY to ₹140.79 crore - Upstox
Immutep Limited Adr Stock (IMMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):